Ampyra
(Dalfampridine)ApprovedSmall molecule
Dalfampridine helps improve walking ability in people with multiple sclerosis by strengthening nerve signals that have been damaged by the disease. It works by blocking potassium channels in the nervous system.[2] Ampyra is currently approved and in use across 5 indications[4].[1]
Ampyra is one of 92 small molecule programs targeting Anterior Ischemic Optic Neuropathy. It is currently in Approved.
5
Indications
14
Total Trials
3
Active Trials
91
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Ampyra
MMerz Pharmaceuticals GmbH
Approved
Betaseron
BayerPreclinical
Kesimpta
NovartisPreclinical
Tysabri
BiogenPreclinical
Zinbryta
RochePreclinical
Flomax
SanofiPreclinical
Novantrone
PfizerPreclinical
Pred Forte
NovartisPreclinical
Myfortic
NovartisPreclinical
Circadin
NNeurim Pharmaceuticals Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Sclerosis4 trials
Spinal Cord Injury2 trials
Anterior Ischemic Optic Neuropathy1 trial
5 more indications
Safety and Efficacy1 trial
Adult1 trial
Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults
Completed·—·Phase 2·NCT02656160·13 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 22, 2010
AMPYRA
NDA NDA022250
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ampyra drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Dalfampridine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- MMerz Pharmaceuticals GmbH